Development and characterization of an αvβ6-specific diabody and a disulfide-stabilized αvβ6-specific cys-diabody

被引:10
|
作者
White, Jason B. [1 ]
Boucher, David L. [1 ]
Zettlitz, Kirstin A. [2 ]
Wu, Anna M. [2 ]
Sutcliffe, Julie L. [1 ,3 ,4 ,5 ]
机构
[1] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
[3] Univ Calif Davis, Div Hematol Oncol, Dept Internal Med, Sacramento, CA 95817 USA
[4] Univ Calif Davis, Ctr Mol & Genom Imaging, Davis, CA 95616 USA
[5] Univ Calif Davis, Radiochem Res & Training Facil, Davis, CA 95616 USA
基金
美国能源部;
关键词
Diabody; Fluorine-18; Copper-64; alpha v beta(6) integrin; Site-specific conjugation; Radiolabeling; ENGINEERED ANTIBODY FRAGMENTS; ALPHA-V-BETA-6; INTEGRIN; IN-VIVO; N-SUCCINIMIDYL; UP-REGULATION; IMMUNO-PET; CANCER; EXPRESSION; CARCINOMA; ALPHA(V)BETA(6);
D O I
10.1016/j.nucmedbio.2015.07.014
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: This work describes the development and characterization of two antibody fragments that specifically target the alpha v beta(6) integrin, a non-covalent diabody and a disulfide-stabilized cys-diabody. The diabodies were analyzed for their ability to bind both immobilized and cell surface-bound alpha v beta 6. Radiolabeling was done using non-site-specific and site-specific conjugation approaches with N-succinimidyl 4-[F-18]fluorobenzoate ([F-18]-SFB) and the bifunctional chelator 1,4,7-triazacyclononane-triacetic acid maleimide (NOTA-maleimide) and copper-64 ([Cu-64]), respectively. The affects of each radiolabeling method on RCY, RCP, and immunoreactivity were analyzed for the [F-18]-FB-alpha v beta(6) diabody, [F-18]-FB-alpha v beta(6) cys-diabody, and the [Cu-64]-NOTA-alpha v beta(6) cys-diabody. Methods: Diabodies were constructed from the variable domains of the humanized 6.3G9 anti-alpha v beta(6) intact antibody. The anti-a,136 cys-diabody was engineered with C-terminal cysteines to enable covalent dimerization and site-specific modification. Biochemical characterization included SDS-PAGE, Western blot, and electrospray ionization to confirm MW, and flow cytometry and ELISA experiments were used to determine binding affinity and specificity to alpha v beta(6). The diabodies were radiolabeled with [F-18]-SFB and in addition, the anti-alpha v beta(6) cys-diabody was also radiolabeled site-specifically using NOTA-maleimide and [Cu-64]. Immunoreactivities were confirmed using in vitro cell binding to DX3Puro beta(6) (alpha v beta(6)+) and DX3Puro (alpha v beta(6)-) cell lines. Results: The diabodies were purified from cell culture supernatants with purities >98%. Subnanomolar binding affinity towards alpha v beta(6) was confirmed by ELISA (diabody IC50 = 0.8 nM, cys-diabody IC50 = 0.6 nM) and flow cytometry revealed high specificity only to the DX3Puro beta(6) cell line for both diabodies. RCYs were 22.6% +/- 3.6% for the [F-18]-FB-alpha v beta(6) diabody, 83% +/- 1.7% for the [F-18]-FB-alpha v beta(6) cys-diabody and 43.5% +/- 55% for the [Cu-64]-NOTA-alpha v beta(6) cysdiabody. In vitro cell binding assays revealed excellent specificity and retention of immunoreactivity ([F-18]-FB-alpha v beta(6) diabody = 58.7% +/- 6.7%, [F-18]-FB-alpha v beta(6) cys-diabody = 80.4% +/- 4.4%, [Cu-64]-NOTA-alpha v beta(6) cys-diabody = 59.4% +/- 0.6%) regardless of the radiolabeling method used. Conclusions: Two novel diabodies with excellent binding affinity and specificity for the alpha v beta(6) integrin in vitro were developed. Radiolabeling of the diabodies with fluorine-18 ([F-18]) and [Cu-64] revealed advantages and disadvantages with regards to methodologies and RCYs, however immunoreactivities were well preserved regardless of radiolabeling approach. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:945 / 957
页数:13
相关论文
共 50 条
  • [1] Site-specific radiolabeling of an anti-αvβ6 cys-diabody with copper-64: Preclinical evaluation as a PET imaging agent
    White, Jason
    Boucher, David
    Hu, Lina
    Sutcliffe, Julie
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [2] Optimisation of αvβ6-specific peptides for use in targeted radionuclide therapy
    Kashani, R.
    Khan, N.
    Foster, J.
    Young, J.
    Marshall, J.
    Sosabowski, J. K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S142 - S142
  • [3] Site-specific cys-diabody conjugates for optical imaging applications
    Bartlett, Derek
    Ray, Sunetra
    Rahib, Lola
    Wu, Anna
    Singh, Rajendra
    Behrenbruch, Christian
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [4] Synthesis and characterization of a high-affinity αvβ6-specific ligand for in vitro and in vivo applications
    Li, Shunzi
    McGuire, Michael J.
    Lin, Mai
    Liu, Ying-Horng
    Oyama, Tsukasa
    Sun, Xiankai
    Brown, Kathlynn C.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (05) : 1239 - 1249
  • [5] Generation and Characterization of a Diabody Targeting the αvβ6 Integrin
    Kogelberg, Heide
    Miranda, Enrique
    Burnet, Jerome
    Ellison, David
    Tolner, Berend
    Foster, Julie
    Picon, Carmen
    Thomas, Gareth J.
    Meyer, Tim
    Marshall, John F.
    Mather, Stephen J.
    Chester, Kerry
    PLOS ONE, 2013, 8 (09):
  • [6] Using in vitro phage display to identify αvβ6-specific peptides as molecular imaging probes
    Hu, Lina
    White, Jason
    Cumming, Robin
    Bauer, Nadine
    Boucher, David
    Sutcliffe, Julie
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [7] Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus
    Moore, Kate M.
    Desai, Ami
    Delgado, Bea de Luxan
    Trabulo, Sara Maria David
    Reader, Claire
    Brown, Nicholas F.
    Murray, Elizabeth R.
    Brentnall, Adam
    Howard, Philip
    Masterson, Luke
    Zammarchi, Francesca
    Hartley, John A.
    van Berkel, Patrick H.
    Marshall, John F.
    THERANOSTICS, 2020, 10 (07): : 2930 - 2942
  • [8] ImmunoPET Imaging of αvβ6 Expression Using an Engineered Anti-αvβ6 Cys-diabody Site-Specifically Radiolabeled with Cu-64: Considerations for Optimal Imaging with Antibody Fragments
    Jason B. White
    Lina Y. Hu
    David L. Boucher
    Julie L. Sutcliffe
    Molecular Imaging and Biology, 2018, 20 : 103 - 113
  • [9] ImmunoPET Imaging of αvβ6 Expression Using an Engineered Anti-αvβ6 Cys-diabody Site-Specifically Radiolabeled with Cu-64: Considerations for Optimal Imaging with Antibody Fragments
    White, Jason B.
    Hu, Lina Y.
    Boucher, David L.
    Sutcliffe, Julie L.
    MOLECULAR IMAGING AND BIOLOGY, 2018, 20 (01) : 103 - 113
  • [10] In vitro and in vivo evaluation of the effects of aluminum [18F]fluoride radiolabeling on an integrin αvβ6-specific peptide
    Hausner, Sven H.
    Bauer, Nadine
    Sutcliffe, Julie L.
    NUCLEAR MEDICINE AND BIOLOGY, 2014, 41 (01) : 43 - 50